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Moreover, our selection criteria with respect to intraventricular
asynchrony were highly restrictive and may have led to selection of
patients with a very unfavorable prognosis.
Fourth, we agree with Dr. Gasparini and colleagues that the
screening of patients suitable for CRT based on merely clinical
criteria may be sufficient in specific settings. However, we are of
the opinion that this simplification could increase the number of
non-responders to CRT: this issue is critical, and current research
for the identification of responders is in active development. There
is evidence that left intraventricular asynchrony detected at echo-
cardiography may represent the best parameter for the identifica-
tion of responders to CRT (3,4). Therefore, we are convinced that
the selection of patients for CRT should necessarily include the
evaluation of mechanical asynchrony, the latter representing the
pathophysiologic substrate for resynchronization pacing in heart
failure patients.
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Cerebroprotection
Mediated by Angiotensin II
I read with great interest the provocative study by Fournier et al.
(1) on cerebroprotection mediated by angiotensin II. The investi-
gators state that beta-blockers are remarkably ineffective in reduc-
ing the risk of stroke; however, they cite three studies all performed
with one beta-blocker, atenolol, which has never been proven to
reduce sudden death.
In general, the results of multiple studies with one drug cannot
be interpreted as representing the class of that drug. In the case of
beta-blockers in particular, publication of the Beta-blocker Eval-
uation of Survival Trial (BEST) (2), which failed to replicate the
mortality reduction demonstrated by bisoprolol, metoprolol ex-
tended release, and carvedilol in systolic heart failure, clearly
established the fallacy of assuming a class effect for the benefit of
beta-blockers for that particular indication. Furthermore, in the
recently published Carvedilol Or Metoprolol European Trial
(COMET) (3), the stroke rate was reduced significantly (67%)
with carvedilol compared with the short-acting metoprolol tartrate
(4). Thus, the investigators need to limit their conclusion of the
ineffectiveness of beta-blockers to atenolol and avoid invoking
beta-blockers as a class in this argument.
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REPLY
Dr. Ghali raises an interesting point about our study (1) that
deserves to be scrutinized. In hypertension, beta-blockers as a class
have never been shown to reduce heart attacks or strokes (2,3). This
is true for atenolol in several prospective placebo-controlled random-
ized trials, but also for propranolol in the Medical Research Council
(MRC) study (4) and for oxprenolol in the International Prospective
Primary Prevention Study in Hypertension (IPPPSH) (5). In Cardiac
Insufficiency Bisoprolol Study (CIBIS-II), the rate of hospitalization
for a stroke was almost twice as high in the bisoprolol arm as in the
placebo arm (6). Thus, there are several prospective randomized
studies with atenolol, propranolol, oxprenolol, or bisoprolol docu-
menting that beta-blockers are not efficacious in reducing strokes.
A notable exception that Dr. Ghali mentioned is the Carvedilol
Or Metoprolol European Trial (COMET) in congestive heart
failure patients (7). However, carvedilol is a drug that is distinctly
different from traditional beta-blockers in that it does have some
alpha-blocking properties and other features that exert a more
favorable effect on systemic hemodynamic, metabolic endocrine
findings, and target organ disease than do traditional beta-blockers
(8). We also should emphasize that a stroke reduction in conges-
tive heart failure without hypertension cannot necessarily be
extrapolated to uncomplicated hypertension. Indeed, heart failure
per se is a risk factor for stroke, but the pathogenesis is different
from the one in hypertension and often involves emboli of cardiac
origin. Because carvedilol was superior to metoprolol in preventing
congestive heart failure and sudden death, it is likely that it
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